Astra Zeneca doses first participants with COVID-19 variant vaccine - AZD2816

This phase II/III trial will administer AZD2816 to previously vaccinated or non-vaccinated subjects, the latter who will be administered with a two-dose regimen. The vaccine has had minor genetic alterations to the spike protein based on the beta (B.1.351/South African) variant.

Source:

PharmaTimes